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Neutralization of interleukin-17 rescues amyloid-β-induced neuroinflammation 
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Background and Purpose: Alzheimer's disease (AD) is a common neurodegenerative 
disease characterized by a neuroinflammatory state and to date, there is no cure and its 
treatment represents a large unmet clinical need. The involvement of T helper 17 cells in the 
pathogenesis of AD-related neuroinflammation has been reported in several studies, however 
the role of the main cytokine, IL-17, has not been well addressed. Herein, we investigate the 
effects of IL-17 neutralizing antibody (IL-17Ab) injected by intracerebroventricular (ICV) or 
intranasal (IN) routes on amyloid-β-induced neuroinflammation and memory impairment in 
mice. 
Experimental Approach: Amyloid-β (Aβ)1–42 was injected into cerebral ventricle of adult 
CD1 mice. These mice received IL-17Ab via ICV either at 1 hour prior to Aβ1–42 injection or 
IN 5 and 12 days after Aβ1–42 injection. After 7- and 14-days of Aβ1-42 administration, we 
evaluated olfactory, spatial and working memory and performed biochemical analyses on 
whole brain and specific brain areas. 
Key Results: Remarkably, ICV pre-treatment with IL-17Ab remarkably reduced Aβ1–42-
induced neurodegeneration, improved memory function and prevented the increase of pro-
inflammatory mediators in a dose dependent manner at 7- and 14-days. Similarly, the double 
IN administration of IL-17Ab after Aβ1–42 injection reduced neurodegeneration, memory 
decline and the levels of pro-inflammatory mediators and cytokines. 
Conclusion and Implications: These findings suggest that IL-17Ab reduces 
neuroinflammation and behavioral symptoms induced by Aβ. The efficacy of IL-17Ab IN 
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administration in reducing Aβ1–42 neurodegeneration points to a possible future therapeutic 
approach in patients with AD. 
 
Keywords: Alzheimer, Immunotherapy, Intranasal, IL-17, Neuroinflammation. 
 
Introduction 
Alzheimer's disease (AD) is a neurodegenerative disorder and one of the most common forms 
of dementia worldwide (Liu et al., 2017). Pathologically, it is characterized by the deposition 
of extracellular amyloid-β (Aβ) in the brain causing neuronal death in the neocortex and 
hippocampus leading to irreversible cognitive impairment and behavioral alterations (Taylor 
et al., 2002). 
A large body of experimental evidence supports the view that amyloid plaques are (Taylor et 
al., 2002) key to driving AD pathogenesis through activation of both innate and adaptative 
immune pathways (Hardy & Selkoe, 2002). The ensued neuroinflammatory response sustains 
the production and release of neurotoxic and inflammatory mediators (Schwartz & 
Deczkowska, 2016; Su et al., 2016) through the activation of microglia and astrocytes, 
causing neuronal cell death (Meda et al., 1995; Zuroff et al., 2017) and the release of 
inflammatory neurotransmitters and reactive oxygen species (Tansey et al., 2007).  
The release of mediators leads to recruitment of additional monocytes and lymphocytes 
through the blood brain barrier, thus promoting their proliferation, and resulting in further 
release of inflammatory factors (Das & Basu, 2008). Inflammatory markers have been 
detected not only in the brain but also in the bodily fluids of AD patients, reflecting a 
systemic neuropathological change (Bagyinszky et al., 2017). 
T lymphocytes are particularly involved in the inflammatory response associated with AD. It 
has been shown that activated T cells can easily cross the blood brain barrier contributing to 
the ongoing inflammatory repertoire and disease pathogenesis (Togo et al., 2002). In this 
context, several studies reported the importance of T helper (Th) 17 cells and Th17-derived 
pro-inflammatory cytokines such as IL-17, IL-21, IL-22, IL-23, GM-CSF and IFN-γ in the 
pathogenesis of AD (Saresella et al., 2011) and in other neurological disorders such as 
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multiple sclerosis and Parkinson's disease (Miossec & Kolls, 2012; Tahmasebinia & 
Pourgholaminejad, 2017) 
Increased levels of Th17 transcription factor RORγt, in addition to IL-17 and IL-22, have 
been found in the brain of AD animal models (Zhang et al., 2013; Zhang et al., 2015) and the 
increase of Th17/IL-17A axis is sustained by Aβ-induced oxidative stress (Solleiro-
Villavicencio & Rivas-Arancibia, 2017). Furthermore, Zenaro et al. (2015) showed a role for 
neutrophils in AD-like pathogenesis and cognitive impairment through the release of 
neutrophil extracellular traps and IL-17 into the brain, suggesting that the inhibition of 
neutrophil trafficking and related neuro-inflammatory onset may be beneficial in this 
pathology. Therefore, the increased level of IL-17 and the activation of its signal transduction 
pathway seem to be involved in neurodegeneration and memory impairment, typical of AD 
(Diaz et al., 2012; Yin et al., 2009). Moreover, a growing number of studies suggest the 
involvement of IL-17 in the negative regulation of adult hippocampal neurogenesis (Liu et 
al., 2014), neuronal differentiation and injury (Wang et al., 2009).  
Given the well-known contribution of neuroinflammation in AD and the stringent 
involvement of the pro-inflammatory cytokine IL-17, we decided to examined whether the 
IL-17 neutralizing antibody via intracerebroventricular (ICV) or intranasal (IN) routes could 
ameliorate amyloid-β-induced neuroinflammation and memory impairment. 
 
Materials and Methods 
Reagents 
Recombinant mouse IL-17 (also known as IL-17A) neutralizing antibody (IL-17Ab, 
monoclonal rat IgG2A, clone 50104), its related isotype control (IgG2A, clone 54447) and 
proteome profiler mouse cytokine Array Kits (cat. ARY006) were purchased from R&D 
System (Milan, Italy). Aβ1–42 (cat. 1428) and Aβ42-1 (cat. 3391) amyloids peptides were 
purchased from Tocris (Milan, Italy). For western blot analysis, the primary antibodies mouse 
monoclonal anti-β Amyloid (MOAB-2) were obtained from Novus Biologicals (Milan, Italy). 
Mouse monoclonal anti-actin was obtained from Sigma–Aldrich Co. (Milan, Italy). The 
HRP-conjugated IgG secondary antibodies (anti-mouse) were purchased from Dako 
(Copenhagen, Denmark). For immunofluorescence analysis, the rabbit polyclonal anti-Glial 
Fibrillary Acid Protein (GFAP) (cat. Z0334) was obtained from Dako Cytomation 
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(Copenhagen, Denmark) and rabbit anti-ionized calcium binding adapter molecule (Iba-1) 
(cat. 019-19741) was purchased from Wako Chemicals (Neuss, Germany). The secondary 
antibody donkey anti-rabbit IgG Alexa Fluor 488 (cat. A21206) was purchased from 
Invitrogen (USA). The Aβ1-42 and S100B kit were purchased from BioVendor (Rome, Italy). 
Unless otherwise stated, all the other reagents were from Carlo Erba (Milan, Italy).  
Animals 
CD-1 male mice (10–14 weeks of age, 25–30 g of weight) were purchased from Charles 
River (Milan, Italy) and kept in an animal care facility under controlled temperature, 
humidity and on a 12 h:12 h light:dark cycle, with ad libitum access to water and standard 
laboratory chow diet.  All experimental procedures were carried out in compliance with the 
international and national law and policies (EU Directive 2010/63/EU for animal 
experiments, ARRIVE guidelines and the Basel declaration including the 3Rs concept) 
(Kilkenny et al., 2010; McGrath & Lilley, 2015) and approved by Italian Ministry of Health. 
All procedures were carried out to minimize the number of animals used (n=6 per group) and 
their suffering.  
In vivo animal model and drugs administration 
Mice were randomly divided into 13 experimental groups, as schematically reported in Table 
1, counterbalancing body weight variation across groups. For the in vivo model, we used a 
well-established method consisting of a direct Aβ injection as recently described (Maione et 
al., 2018a). Briefly, before the injection, Aβ1–42 protein was dissolved in PBS (1μg μl
-1
) in 
tubes that were sealed and incubated for 1 day at 37 °C to allow peptide assembly state. 
Anesthetized mice (mixture of N2O and O2 70:30 w v
-1 
containing 2% isoflurane) were 
injected with aggregated Aβ1–42 peptide (3μg 3μl
-1
) or its inactive control peptide Aβ42-1 (3μg 
3μl-1) into cerebral ventricle at a rate of 1μl min-1, using a micro-syringe (10μl, Hamilton) 
according to the procedure previously described (Maione et al., 2018a). The needle was 
removed after 3 min using three intermediate steps with 1-min inter-step delay to minimize 
backflow. Another experimental group (Ctrl) included mice that received the surgery 
procedure and Aβ peptide vehicle injection. After surgery and Abs administration, mice were 
placed on a thermal pad until they awakened. All procedures were performed with strict 
aseptic manipulation. Hamilton syringe used for ICV injections was repeatedly washed with 
distilled water followed by flushing with 1 mg ml
-1
 bovine serum albumin solution, in order 
to avoid non-specific binding of peptides to glass. To evaluate IL-17Ab protection profile 
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against Aβ1–42 peptide-induced amyloidosis, we used two routes of injection: a single ICV 
administration of IL-17Ab (0.01-1μg 3μl-1) and its related isotype control IgG2A administered 
at a maximum dose (1μg 3μl-1), 1h prior to the Aβ1–42 injection, or IN administration of IL-
17Ab (0.01-1μg 10μl-1) and its related isotype control IgG2A administered at highest dose 
(1μg 10μl-1), at 5 and 12 days post peptide injection (Fig 1). Taking into account several 
previously published reports (Southam et al., 2002; Pires et al., 2009), we performed IL-
17Ab IN administration considering the effects of volume, body position and anesthesia. 
Behavioral studies 
At 7- and 14-days post Aβ1-42 administration, mice were tested for novel object recognition, 
olfactory discrimination, Y-maze and Morris water maze (Fig 1). All tests were performed 
between 9 am and 2 pm in an experimental room with sound isolation and dim light. The 
animals were carried to the test room for at least 1 hour for acclimation. Behavior was 
monitored using a video camera positioned above the apparatus and the videos analyzed in a 
blinded fashion using video tracking software (Any-maze, Stoelting, Wood Dale, IL, USA). 
Novel object recognition (NOR) 
The NOR task exploits a mouse’s natural tendency to explore a novel object after previous 
exposure to two identical objects. Mice were habituated for 10 minutes into the arena to 
reduce anxiety associated with the novel arena (plastic arena 30 x 30 x 50 cm). After this 
habituation stage, mice were ready to perform the task, which was conducted using two trials 
(familiarization trial [T1] and a test trial [T2]) separated by 30 minutes. During T1, mice 
were allowed to explore for 10 minutes two identical objects (plastic screw-top tubes) 
secured to the floor using a small amount of Blu Tack in habituated arenas. For T2, one 
identical object from T1 was replaced with a novel object (small green flask) and mice were 
allowed to freely explore for 5 minutes. T1 and T2 were recorded using a video camera and 
analyzed for the time spent interacting with the novel object. All arenas were cleaned with 
80% ethanol prior the test. Novel object exploration was calculated in T2 by (T novel x 
100)/(T novel + T identical) with exploration defined as the nose being less than 1 cm from 
the object when facing the object or actively engaging with the object by sniffing or paw 
touching. Climbing on the object was not considered exploratory. 
Y-maze task 
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Spontaneous alternation is a measure of spatial working memory. Such short-term working 
memory was assessed by recording spontaneous alternation behavior during a single session 
in the Y-maze (made with three arms, 40 cm long, 120
○
C separate) positioned at the exact 
same location for all procedures. Each mouse was placed at the end of one arm and allowed 
to move freely through the maze during a 5 min session. The series of arm entries were 
visually recorded. An arm choice was considered only when both fore paws and hind paws 
fully entered into the arm. The Y-maze was cleaned after each test with 80% ethanol to 
minimize odor cues. Alternation was defined as a successive entrance onto the three different 
arms. The number of correct entrance sequences (e.g., ABC, BCA) was defined as the 
number of actual alternations. The number of total possible alternations was therefore the 
total number of arm entries minus two, and the percentage of alternation was calculated as 
actual alternations/total alternations x 100 (D'Agostino et al., 2012). 
Morris water maze 
To assess spatial memory function, mice were tested by Morris water maze which consisted 
of a circular pool (diameter 170 cm, height 60 cm) with a transparent platform (10 cm in 
diameter), submerged under the water surface (1.5 cm). The water temperature of 24±1 °C, 
light intensity and external visual cues in the room were rigorously reproduced. Swimming 
was recorded using a camera capture and analyzed using video tracking software (Any-maze, 
Stoelting, Wood Dale, IL, USA) that divided the pool into four equal quadrants. The platform 
position remained stable during 4 days in one of the four quadrants. Training phase consisted 
of four swims per day for 4 days, with about a 15-min inter-trial time. Each of the four 
starting positions was used in randomized order. Each trial was started by placing a mouse 
into the pool, facing the wall of the tank and terminated as soon as the animal reach the 
platform with a cut-off of 60 s. After the test, each mouse was kept warm for an hour and 
then returned to their home cage. Average of the four trials for each mouse and then the 
average for each group to give a single path length and escape latency expressed as mean ± 
SEM, was calculated for each training day. A probe test was also performed 1 h after the last 
swim on day 4. The platform was removed and each animal was allowed a free 60 s swim. 
The time spent in the quadrant where the platform was previously placed, was determined. A 
higher percentage of time spent in the platform quadrant is interpreted as a higher level of 
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The task was based on the fact that mice prefer places with their own odor (familiar 
compartments) instead of places with unfamiliar odors. In this test, mice had access to 2 
adjacent identical chambers separated by an intermediate zone. One chamber contained 
familiar bedding from its home cage over the last 48 hours (familiar) whereas the other 
contained fresh bedding (non-familiar). Mice were placed individually into the intermediate 
zone and allowed to freely explore each chamber for 10 minutes. Rodents are capable of 
discriminating familiar versus non-familiar chambers since they prefer their odor to no odor 
at all (D’Agostino et al., 2012). The time spent in each chamber was recorded and analyzed. 
An olfactory discrimination index was generated according to the following formula: T 
familiar/(T familiar + T non-familiar), where T equal time and/or 0.5 as final value were 
considered as no preference. 
Cytokines and Chemokines protein array 
All mice were euthanized and brains immediately removed. Total brain, prefrontal cortex and 
hippocampus (half of the brain was used for cytokine/chemokine analysis and the half for 
further dissection and related analysis) were collected into a 2.0 ml tube for an immediate 
preservation in liquid nitrogen and a successive storage at -80
○
C. The isolated tissues were 
homogenized in ice-chilled Tris–HCl buffer (20 mM, pH 7.4) containing 0.32 M sucrose, 1 
mM EDTA, 1 mM EGTA, 1 mM PMSF, 1 mM sodium orthovanadate and one protease 
inhibitor tablet per 50 ml of buffer. Protein concentration was determined by the BioRad 
protein assay kit (BioRad, Italy). Equal volumes (1.5 ml) of the homogenates were then 
incubated with the pre-coated proteome profiler array membranes according to the 
manufacturer’s instructions. Dot plots were detected by using the enhanced 
chemiluminescence (ECL) detection kit and Image Quant 400 GE Healthcare software (GE 
Healthcare, Italy) and successively quantified using GS 800 imaging densitometer software 
(Biorad, Italy). 
Western blot analysis  
Whole brain tissue homogenates (35 μg of protein) were subjected to SDS-PAGE (10% gel) 
using standard protocols as previously described (Blaine Stine et al., 2011; Maione et al., 
2018a). The proteins were transferred to PVDF membranes in the transfer buffer [25 mM 
Tris–HCl (pH 7.4) containing 192 mM glycine and 20% v/v methanol] at 400 mA for 2 h. 
The membranes were saturated by incubation for 2 h with non-fat dry milk (5% wt/v) in PBS 
supplemented with 0.1% (v/v) Tween 20 (PBS-T) for 2 h at RT and then incubated with 
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1:1000 dilution of anti-β Amyloid or with 1:2000 dilution of anti-actin (after stripping) over-
night at 4
○
C and then washed 3 times with PBS-T. Blots were incubated with a 1:3000 
dilution of horseradish peroxidase-conjugated secondary antibody for 2 h at RT, washed 3 
times with PBS-T. Protein bands were detected by using the enhanced chemiluminescence 
(ECL) detection kit and Image Quant 400 GE Healthcare software (GE Healthcare, Italy). 
Protein bands were quantified using GS 800 imaging densitometer software (Biorad, Italy) 
and normalized with respective actin.  
ELISA assay  
Enzyme-linked immunosorbent assay for Aβ1-42 and S100B was carried out on brain 
homogenates. Briefly, 100 µl of tissue supernatants, diluted standards, quality controls and 
dilution buffer (blank) were added to a pre-coated plate with monoclonal anti-Aβ1-42 or 
S100B for 2 h. After washing, 100 µl of biotin labeled antibody was added for 1 h. The plate 
was washed and 100 µl of streptavidin-HRP conjugate was added and the plate was incubated 
for a further 30 min period in the dark. The addition of 100 µl of the substrate and stop 
solution represented the last steps before the reading of absorbance (measured at 450 nm) on 
a microplate reader. Antigen levels in the samples were determined using a standard curve of 
Aβ1-42 or S100B and expressed as μg ml
-1
. 
Immunofluorescence analysis  
Immunofluorescence was performed by the free-floating method. Briefly, mice were trans-
cardially perfused with phosphate buffered saline (PBS) pH 7.4 solution followed by 4% 
paraformaldehyde. Brains were removed from the skull and fixed overnight in the 4% 
paraformaldehyde solution at 4°C. After being transferred in 30% sucrose solution, brains 
were cut into 25 µm sections using a cryostat microtome (Leica, Wetzlar, Germany) 
throughout the hippocampus. Slices were blocked for 1 h in 0.1% bovine serum albumin 
(BSA) solution and then incubated overnight at 4°C with primary antibody for the microglial 
cell marker Iba-1 (1:1000) or astrocytes cell marker GFAP (1:1000). The day after, sections 
were washed and incubated for 1 h with secondary antibody solution (donkey anti-rabbit IgG 
Alexa Fluor 488; 1:1000). Slices were washed, mounted onto glass slides and cover-slipped 
with Vectashield mounting medium (Vector Laboratories, Burlingame, CA), and images 
taken by Leica DM RB microscope using the Leica Application Suite software V.4.1.0 and 
photographed at 20X magnification. For quantification analysis, from each section containing 
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the hippocampus (bregma level -1.82mm) activated astrocytes and microglia were counted 
from chosen equal area and analyzed with Image J software (NIH, Bethesda, MD, USA).  
Myeloperoxidase assay 
Leukocyte myeloperoxidase (MPO) activity was assessed by measuring the H2O2-dependet 
oxidation of 3,3’,5,5’-tetramethylbenzidine (TMB) as previously reported (Maione et al., 
2009). Tissues (total brain) were homogenized for 35 sec in a solution composed of 
hexadecyltrimethylammonium bromide (HTAB; 0.5% w v
-1
) in 50 mM sodium phosphate 
buffer pH 5.4. After homogenization, samples were centrifuged (4000 g) for 20 min and the 
supernatant used for the assay. Aliquots of 20 µl were incubated with 160 μl of TMB and 20 
μl of H2O2 (in 80 mM phosphate buffer, pH 5.4) in 96-well plates. Plates were incubated for 
5 min at RT and optical density was read at 620 nm using a plate-reader (Biorad, Italy). 
Assay were performed in duplicates and normalized for protein content. 
Statistical analysis 
The results obtained were expressed as the mean ± SEM. Statistical analysis were performed 
by using one-way ANOVA followed by Bonferroni or Dunnett's post-test when comparing 
more than two groups. GraphPad Prism 6.0 software (San Diego, CA, USA) was used for 
analysis. Data were considered statistically significant when a value of P≤0.05 was achieved. 
The data and statistical analysis comply with the recommendations on experimental design, 
analysis (Curtis et al., 2015) and data sharing and presentation in preclinical pharmacology 
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IL-17Ab alleviates the Aβ1-42-induced olfactory and object recognition impairment in a 
dose dependent manner 
Consistent with the demonstration that olfactory dysfunction occurs at the early stage of 
amyloid-β-induced pathology, the administration of Aβ1-42 (3μg 3μl
-1
 ICV) significantly 
decreased the capability of mice to discriminate new and familiar odors when tested 7- and 
14-days later (Fig 2A-B) compared to Ctrl and Aβ42-1 groups. Interestingly, administration of 
different doses of IL-17Ab injected both ICV (0.01-1μg 3μl-1) and IN (0.01-1μg 10μl-1) was 
shown to attenuate the olfactory dysfunction significantly in a dose and time dependent 
manner, both at 7- and 14-days following Aβ1-42-administration.  
The administration of Aβ1-42 significantly reduced the delta time in the NOR test at day 7 and 
more significantly at day 14 (Fig 2C-D). Prior single ICV (0.01-1μg 3μl-1) injection of IL-
17Ab significantly attenuated the Aβ1-42 related impairment in the NOR task in a dose and 
time-dependent manner compared to Ctrl and Aβ42-1 groups (Fig 2C-D). The injection of IL-
17Ab IN, at different doses (0.01-1μg 10μl-1) on day 5, after Aβ1-42 induced-impairment had 
no effect on day 7, while after the second IN administration on day 12, the higher dose was 
shown to reduce the impairment in the NOR test at day 14. IL-17Ab alone and IL-17Ab 
isotype control administered via ICV and IN did not alter both olfactory and object 
recognition impairment (Fig 2). 
IL-17Ab ameliorates Aβ1-42-induced spatial and working memory decline 
Based on previous results, we selected the most active doses (1μg for both ICV and IN 
administration) of IL-17Ab to test spatial and working memory by the Morris water maze and 
Y-maze test. Aβ1-42 (3μg 3μl
-1 
per mouse, ICV) injection induced an increase of escape 
latency in Morris water maze, specifically during the second day of the training phase, while 
the acquisition of the platform position was faster in mice treated with IN injection of IL-
17Ab (Fig 3A). All groups showed the same average speed (Fig 3B). Two different cohorts 
of mice were subjected to the probe test at 7 or 14 day following Aβ1-42 injection (Fig 3C-D). 
The time that Aβ1-42 injected mice spent in the target quadrant was significantly shorter on 
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both day 7 and 14 compared to Ctrl and Aβ42-1 groups. On day 7, no significant improvement 
was observed regarding the time spent in the target quadrant in mice treated with the active 
doses of IL-17Ab by ICV while the IN route significantly increased the time spent in the 
target quadrant, compared to mice that received only Aβ1-42 (Fig 3C). On day 14, the active 
doses of IL-17Ab, administered both ICV and IN, significantly increased the time spent in the 
target quadrant (Fig 3D). No significant effects were observed in IL-17Ab administered ICV 
or IN alone, Aβ42-1 and IL-17Ab isotype control groups (Fig 3). These results were also 
confirmed by the track plots on day 7 and 14 presented in Fig 3E.  
Percent of correct alternations in the Y-maze test was then analyzed on day 7- and 14-days 
after Aβ1-42 injection (Fig 4). Single prior ICV (1μg 3μl
-1
) administration and double 
administration of IL-17Ab IN (1μg 10μl-1) after the Aβ1-42 significantly attenuated the 
impairment of spontaneous alternation induced by Aβ1-42 on both day 7 and day 14, in equal 
manner (Fig 4A-C). Aβ1-42 and IL-17Ab treatments did not affect the total number of arm 
entries at these dosages (Fig 4B-D). No significant effects were observed in Aβ42-1, IL-17Ab 
administered ICV or IN alone and in IL-17Ab isotype control groups (Fig 4). 
Effect of IL-17Ab administration on Aβ1-42, S100B and myeloperoxidase levels 
We began our biochemical analysis by confirming the behavioural findings with the 
association of Aβ1-42 level in the brain. As expected, Aβ1-42 was significantly higher in the AD 
group compared to control, while its level was significantly lower in IL-17Ab ICV and IL-
17Ab IN treated-group (Fig 5A). This correlation failed to reach significance in Aβ42-1, IL-
17Ab administered ICV or IN alone and in IL-17Ab isotype control groups. These results 
were supported by the simultaneously presence of Aβ monomers and large oligomers (most 
likely dimers and tetramers), at both 7- and 14-days post model induction, in mice injected 
with fibrillated Aβ peptide compare to not-fibrillated-injected mice (Supplementary Fig 1).  
Based on these findings, we decided to examine S100B levels in total brain homogenates by 
S100B ELISA. As shown in Fig 5B at day 14, Aβ1-42 (3μg 3μl
-1
) induced a significant 
increase in S100B levels compared to Ctrl and Aβ42-1 groups. Single ICV administration of 
IL-17Ab prior the Aβ1-42 (1μg 3μl
-1
), in addition to repeated administration of IL-17Ab by IN 
route (1μg 10μl-1), significantly attenuated S100B levels compared to Aβ1-42 treated mice. No 
differences in S100B levels were detected between ICV and IN groups, suggesting that both 
routes had similar positive effects.  
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We went onto monitor inflammatory leukocyte infiltration, at day 14 post Aβ1-42, by 
measuring MPO activity in brain homogenates. We found a significant increase in MPO 
activity in Aβ1-42 injected mice compared to Ctrl and Aβ42-1 groups respectively. The 
administration of IL-17Ab by ICV (1μg 3μl-1) did not restore MPO activity that was 
significantly reduced by IL-17Ab injected IN (1μg 10μl-1) (Fig 5C). No significant effects 
were observed in IL-17Ab administered ICV or IN alone and in IL-17Ab isotype control 
groups, in terms of S100B levels and MPO activity (Fig 5B-C). 
 
Effect of IL-17Ab administration on Aβ1-42-induced neuroinflammatory activity 
Given that Aβ1-42 injection induces neuroinflammation we investigated the molecular 
mechanisms behind the neuroprotective effect of IL-17Ab, by examining both ICV and IN 
alone (and also their effect prior or after the injection of Aβ1-42 induced impairment) on 
microglial and astrocyte inflammatory responses. To confirm of activation of neural cells, we 
measured expression of GFAP (a marker of astrocyte activation) and Iba-1 (a marker of 
microglia cell activation) in the hippocampus for different experimental groups 14 days post 
Aβ1-42 injection. As expected, Aβ1-42 injected mice showed a significant increase in the 
expression of both GFAP and Iba-1 (Fig 6D and Fig 6J) when compared to Ctrl (Fig 6A and 
Fig 6G). Interestingly, both ICV (1μg 3μl-1) and IN (1μg 10μl-1) injection of IL-17Ab 
significantly reduced astrocyte and microglial proliferative response and activation compared 
to mice that received only Aβ1-42 (Fig 6E-F and Fig 6K-L). GFAP and Iba-1 staining in 
animals receiving IL17Ab alone injected ICV or IN was similar to the Ctrl group (Fig 6B-C 
and Fig 6H-I). 
Modulation of pro-inflammatory cyto-chemokines by IL-17Ab 
Informed by previous results, we also compared the cytokine and chemokine profiles from 
total brain homogenates of selected groups which were also used for the histological analysis. 
A similar analysis was performed on homogenates obtained from the hippocampus and 
prefrontal cortex. As shown in Fig 7, Aβ1-42-treated mice (Fig 7E) displayed a marked 
increase in pro-inflammatory cytokines and chemokines (reference standards shown in 7A) 
compared to Ctrl group (Fig 7B). In particular, we observed a significant increase in the 
expression of classical pro-inflammatory cyto-chemokines such as IL-1α, IL-1β, IL-1r, IL-6, 
IL-17, MIP-1α/β and TNF-α (Fig 7H-J). In line with our in vivo evidence, we observed a 
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reversion of this pro-inflammatory onset in IL-17Ab ICV-treated mice (Fig 7F) which 
became more evident after IL-17Ab IN treatment (Fig 7D). In particular, IN treatment 
induced a significant decrease in terms of IL-1β, IL-17, KC and MIP-2 compared to IL-17Ab 
ICV treatment (Fig 7H-J).  
Interestingly, analyzing the inflammatory profile from homogenized hippocampus (Fig 8A-
G) and prefrontal cortex (Fig 8H-N) tissues, we found a different scenario. In the 
hippocampus, Aβ1-42-treated mice presented an increase in ICAM, SDF-1 and, in particular, 
in IL-17 (Fig 8E) compared to Ctrl (Fig 8B) that were reverted after ICV and IN IL-17Ab 
administration (Fig 8O). In the prefrontal cortex we observed a striking difference only in 
terms of IL-17 expression in Aβ1-42 group (Fig 8L) that was modulated after IL-17Ab ICV 
(Figure 8M) and IN (Fig 8N) treated mice. Cyto-chemokines expression in animals receiving 
IL-17Ab alone injected ICV or IN was similar to Ctrl group in whole brain (Fig 7C-D), 
hippocampus (Fig 8C-D) and prefrontal cortex (Fig 8J-K).  
Discussion and Conclusion 
Inflammation comprises a large set of diseases that trigger a wide variety of human disorders. 
Neurological inflammation and autoimmune disorders are an example of immune-mediated 
inflammation (Newcombe et al., 2018). In local inflammation milieu the concentration of 
pro-inflammatory cytokines e.g. IL-1, IL-2, IL-6, IL-12, IFN-γ, TNF-α, IL-17 and IL-23 or of 
the other inflammatory mediators increases (Kempuraj et al., 2017). Th1 and Th17 cells are 
the main cellular mediators responsible for immune-mediated damage that polarize to the site 
of inflammation in presence of noxious/inflammatory stimuli (D'Acquisto et al., 2010). 
Many studies have suggested a relationship between inflammation severity and Th17 cell-
mediated immune responses (Rostami & Ciric, 2013). The role of Th17 cells has been 
highlighted in several autoimmune disorders including, MS, Inflammatory Bowel Disease 
(IBD), Rheumatoid Arthritis (RA) and Systemic Lupus Erythematosus (SLE) as well as in 
neurological disorders including fronto-temporal dementia, PD, AD and schizophrenia (Liu et 
al., 2014).  
AD is the most common and most studied neurodegenerative disorder. It has become a 
critical issue to human health, especially in aging societies, and therefore it is a research 
hotspot in the global scientific community (Newcombe et al, 2018). It is a multifactorial 
disorder primarily characterized by amyloid plaques deposition in the brain leading to 
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irreversible cognitive impairment and neuroinflammation that mainly involves hippocampus 
and cortex districts (D'Amelio et al., 2018). Although Th17 cells have been acknowledged as 
crucial mediators of AD, the effector cytokine IL-17 responsible for their pathogenicity still 
remains poorly defined and very little is known on its path-physiological role in CNS regions 
(hippocampus and prefrontal cortex) normally compromised in this disease.  
In this study we demonstrate that the neutralization of IL-17 cytokine results in substantial 
functional recovery of amyloid-β-induced neuroinflammation and memory impairment. 
Moreover, we report that IL-17Ab administration (both ICV and IN) can reverse reactive 
gliosis and neuroinflammation as indicated ex vivo by the reduction of Aβ1-42, GFAP, Iba-1, 
S100B and MPO as well as by the inhibition of typical pro-inflammatory cyto-chemokines in 
total brain, and more specifically hippocampal and prefrontal cortex regions. 
In particular, we show that neutralization of IL-17 by a single ICV administration ameliorates 
amyloid-β-like symptoms (in terms of olfactory dysfunction, spatial and working memory) 
both after 7- and 14-days, similarly to what observed after a double IL-17Ab IN 
administration at day 5 and 12. The difference in terms of time of administration is justified 
by previous published observations that found a significant increase of Th17 cytokines 
following 7 days from amyloid-β injection (Zhang et al., 2013; Zhang et al., 2015). 
Moreover, very robust effects were observed when the antibody was administered at dose of 
1μg μl-1 compared to the isotype control or antibody itself, consistent with previous in vivo 
reports (Mi et al., 2011; Fisher et al., 2015; Szabo et al., 2017). It is known that a major, yet 
unmet, objective of neuroprotective/anti-neurodegenerative treatments is to arrest or to slow 
down the fast progression of cognitive impairments. Contingently, behavioral experiments 
showed that the Aβ-dependent impairment in terms of spatial learning, reference memory and 
olfactory memory was dose-dependently prevented and reverted by IL-17Ab treatments. 
Due to the particular anatomical features of the nasal cavity, IN administration has been 
explored as a means of preferential drug delivery to the brain, even though a fraction of the 
drug may be absorbed by the systemic circulation (Fortuna et al., 2014). The route of 
administration used in our work (IN) ensures high brain concentration levels of IL-17Ab 
reaching the olfactory bulb and strongly suggests that the antibody was directly transferred to 
the brain via the olfactory neuronal pathway, circumventing the blood brain barrier. To this 
aim and accordingly to rigorous published papers (Southam et al., 2002; Pires et al., 2009), 
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we have also performed our administration considering the effects of volume, time, body 
position and anesthesia. 
Next, we began our biochemical investigation by confirming the well-replicated behavioural 
findings with the association of Aβ1-42 level in whole brain, as pathology index. As expected, 
Aβ1-42 was significantly higher in the AD group compared with the control group, while its 
level was significantly lower in IL-17Ab ICV and IL-17Ab IN treated-group. In addition, our 
biochemical investigation also revealed that IL-17Abs (both ICV and IN) significantly 
attenuated the production of S100B, a glial-derived protein that is secreted from astrocytes. 
At low concentrations it is considered a neurotrophic factor and neuronal survival protein 
during the development of the nervous system (Van Eldik & Wainwright, 2003). Conversely, 
when overproduced by activated glia, it becomes pathological and inﬂuences disease 
progression by acting as pro-inﬂammatory cytokine, contributing to the exacerbation of 
neuroinﬂammation and neuronal dysfunction. In fact, there is compelling clinical evidence 
that implicate S100B as a component of the neuroinﬂammatory cycle that drives AD 
pathogenesis (Mrak & Grifﬁn, 2005). In this context, it is relevant to highlight that S100B 
levels are increased in activated astrocytes in the brain regions most severely affected by AD, 
and its levels correlate with neuritic plaque progression. Additionally, S100B production can 
be stimulated by mediators associated with AD, including β-amyloid and pro-inﬂammatory 
cytokines (Van Eldik & Wainwright, 2003). Collectively, this highlights the crucial role of 
S100B in AD onset and progression and the relevant effects of IL-17Abs in reducing its 
expression in mouse whole brain. At confirmation of the amelioration of the inflammatory 
scenario by IL-17 neutralizing antibodies, we also observed, by the aim of 
immunofluorescence techniques, that GFAP and Iba-1 expression (as index of astrocytes and 
microglia activation, Gu et al., 2015; Liddelow et al., 2017) were markedly reduced after IL-
17 Abs treatments. 
The vasculature of the blood-brain barrier allows only relatively few leukocytes to enter and 
survey the healthy central nervous system (CNS) (Lefkowitz & Lefkowitz, 2008). However, 
during pathological CNS inflammation (including AD), the number of leukocytes adhering to 
and penetrating the CNS vasculature increases (Crawford et al., 2001; Russo et al., 2018). 
Considering that the enzyme myeloperoxidase (MPO) is a heme-protein abundant in 
circulating phagocytes, tissue neutrophils, and some populations of tissue macrophages but 
also highly expressed in AD brain, where it co-localized with amyloid plaques (Reynolds et 
al., 1999), its abnormal expression and modulation could represent another important aspect 
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to be considered in amyloid-related disorders. Our results show that the expression levels of 
the oxidant producing enzyme MPO is modulated by IL-17Ab both after ICV and IN 
administration. 
In line with previous studies (Xia & Hyman, 1999; Rostasy et al., 2003; Walker et al., 2017), 
we also found increased expression of different pro-inflammatory mediators (IL-1α, IL-1β, 
IL-16, KC, MIP-1, IL-17 and TNF-α) in the total brain of Aβ-treated mice compared to 
control mice (cytokines and chemokines that are found associated with AD pathological 
changes). Interestingly, we demonstrate, for the first time, a significant reduction of these 
pro-inflammatory cascades after both ICV and IN administration of IL-17Ab. Furthermore, 
the comparison of the inflammatory profile from hippocampus and prefrontal cortex tissues 
presented a distinctive induction and modulation of ICAM, SDF-1 and IL-17 in Aβ1-42-treated 
group compared to Ctrl with a complete abrogation of IL-17 in both regions after IL-17Ab 
treatment and a significant reduction of ICAM and SDF-1 only in the hippocampus. This 
difference could be in part correlated with previous observations that have demonstrated that 
systemic Th17/IL-17 response appears prior to hippocampal neurodegeneration compare to 
other CNS districts (Solleiro-Villavicencio & Rivas-Arancibia, 2017). 
Endothelial intercellular adhesion molecule-1 (ICAM) does not only mediate firm adhesion 
of leukocytes to vascular beds but also triggers signalling cascades within the endothelial cell, 
which play a crucial role in modulating subsequent leukocytes diapedesis in CNS, especially 
during inflammatory conditions (Adamson et al., 1999). Furthermore, a number of recent 
reports document that drugs interfering with endothelial ICAM-1 signalling, efficiently 
reduce leukocyte migration both in vitro and in animal models of CNS inflammation 
(Turowski et al., 2005). In this scenario, SDF-1 (also known as chemokine CXCL12) could 
also play a crucial role. While SDF-1 is constitutively expressed in the CNS, its role during 
neuroinflammation still remains unclear. Several reports have shown that SDF-1 moderates 
remyelination and synaptic plasticity (Merino et al., 2015) and, contextually, its 
pharmacological inhibition (Azizi et al., 2014) alleviates the release of inflammatory 
mediators in both sciatic nerve injury and bone cancer models (Shen et al., 2014) as well as 
N-methyl-d-aspartate receptor (NMDAR)-mediated neurotoxicity (Sanchez et al., 2016).  
Taken together, it seems that neutralization of IL-17 could substantially restrain release of 
synergistic cytokines, and thus, expression of inflammatory mediators, which sustain 
eventual progression of CNS damage. This scenario is in accordance with our previous 
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studies where we have demonstrated and emphasized the role of IL-17 as a cytokine that 
sustains rather than induces inflammation. (Maione et al., 2009; Maione et al., 2018b).  
In conclusion, the experimental findings reported here confirm and extend previous evidence 
showing that IL-17 is a detrimental factor for AD, where this distinctive cytokine (especially 
for its selective expression in the hippocampus and prefrontal cortex) could represent a key 
factor for the “self-amplifying” neuroinflammatory onset typical of amyloid-β--related 
disease. Under this perspective, future studies will focus on IL-17 brain physiopathology as 
determinant of the developmental neurotoxicity of widely-diffused CNS-related diseases. 
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I Ctrl - - - - - - 
II IL-17Ab ICV - - - - 1μg 3μl-1 - 
III IL-17Ab IN - - - - - 1μg 10μl-1 
IV Aβ
42–1
 3μg 3μl-1 - - - - - 
V Aβ
1–42
 - 3μg 3μl-1 - - - - 
VI Aβ
1–42
+IgG2A  - 3μg 3μl
-1
 1μg 3μl-1 - - - 
VII Aβ
1–42 
+IL-17Ab ICV - 3μg 3μl-1 - - 0.01μg 3μl-1 - 
VIII Aβ
1–42 
+IL-17Ab ICV - 3μg 3μl-1 - - 0.1μg 3μl-1 - 
IX Aβ
1–42 
+IL-17Ab ICV - 3μg 3μl-1 - - 1μg 3μl-1 - 
X Aβ
1–42 
+IgG2A - 3μg 3μl
-1
 - 1μg 10μl-1 -  
XI Aβ
1–42 
+IL-17Ab IN - 3μg 3μl-1 - - - 0.01μg 10μl-1 
XII Aβ
1–42 
+IL-17Ab IN - 3μg 3μl-1 - - - 0.1μg 10μl-1 
XIII Aβ
1–42 
+IL-17Ab IN - 3μg 3μl-1 - - - 1μg 10μl-1 
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Figure 1. Experimental flow chart for the in vivo model, behavioral studies and biochemical 
and molecular analysis with acute and sub-chronic treatment of IL-17Ab. 
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Figure 2. Effect of IL-17Ab ICV and IN-treated mice on (A-B) olfactory discrimination at 7-
(A) and 14-(B) days and (C-D) on novel object recognition at 7-(C) and 14-(D) days. Data 
were expressed as mean ± SEM. Comparisons by one-way ANOVA with Dunnett's post hoc 
test; 
# #P≤0.01, # # # #P≤0.0001 vs  Ctrl-treated group;  *P≤0.05, **P≤0.01, ***P≤0.001, 
****P≤0.0001 indicate significance of treatment vs  Aβ1 – 4 2  peptide-treated group (N=6 
per group).  
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Figure 3. Escape latency (A) and average speed (B) during training phase in the MWM test. 
Time spent in the target quadrant of the probe test at 7-(C) and 14-(D) days. (E) Schematic 
plots of probe test at 7- and 14-days for all experimental groups. Data were expressed as 
mean ± SEM. Comparisons were by one-way ANOVA with Bonferroni's post hoc test; 
# #P≤0.01 vs  Ctrl-treated group;  *P≤0.05, **P≤0.01 indicate significance of treatment 
vs  Aβ1 – 4 2  peptide-treated group (N=6 per group).  
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Figure 4. Percent of correct alternations (A-C) and total arm entries (B-D) in the Y-maze 
test. Data were expressed as mean ± SEM. Comparisons were by one-way ANOVA with 
Bonferroni’s post hoc test; # ## #P≤0.0001 vs  Ctrl-treated group;  **P≤0.01, 
****P≤0.0001 indicate significance of treatment vs  Aβ1 – 4 2  peptide-treated group (N=6 
per group).  
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Figure 5. Effect of IL-17Ab on the production of (A) Aβ1 – 4 2  (detected by ELISA assay and 
expressed as µg ml
-1
), release of (B) S100B protein (detected by ELISA assay and expressed 
as µg ml
-1
) and (C) MPO activity (detected by enzymatic assay and expressed as mg tissue
-1
) 
in total brain homogenates. Data were expressed as mean ± SEM. Comparisons were by one-
way ANOVA with Dunnett's post hoc test; 
## # #P≤0.0001 vs  Ctrl -treated group;  
*P≤0.05, **P≤0.01, ***P≤0.001 indicate significance of treatment vs  Aβ1 – 4 2  peptide-
treated group (N=6 per group).  
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Figure 6. Representative immunofluorescence staining for GFAP and Iba-1 in the 
hippocampus of (A-G) Ctrl, (B-H) IL-17Ab ICV, (C-I) IL-17Ab IN, (D-J) Aβ1–42, (E-K) 
Aβ1–42 + IL-17Ab ICV or (F-L) IL-17Ab IN-treated mice (scale bar 100µm). Quantitative 
analysis of (M) GFAP and (N) Iba-1 positive cells. Values are expressed as percent mean (± 
SEM) of positive cells of n=6 mice in the hippocampus of Ctrl mice. Comparisons were by 
one-way ANOVA with Bonferroni’s post hoc test; ####P≤0.001 vs Ctrl-treated group; 
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Figure 7. Inflammatory fluids obtained from total brain homogenates of (B) Ctrl, (C) 
IL-17Ab ICV, (D) IL-17Ab IN, (E) Aβ1 – 4 2 ,  (F) Aβ1 – 4 2  + IL-17Ab ICV or (G) 
IL-17Ab IN-treated mice were assessed using (A) a Proteome Profiler cytokine array 
panel (in red modulated cytokines). Mean changes (± SEM) of positive spots of three 
separate experiments with n=6 mice, were expressed as INT/mm
2
 of densitometric values (H-
J). Comparisons were by one-way ANOVA with Dunnett's post hoc test; 
#P≤0.05, 
# #P≤0.01, # # #P≤0.001 vs  Ctrl-treated group;  *P≤0.05, **P≤0.01, ***P≤0.001 indicate 
significance of treatment vs  Aβ1 – 4 2  peptide-treated group.  
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Figure 8. Inflammatory fluids obtained from (A-G) hippocampus and (H-N) 
prefrontal cortex homogenates of (B and  I) Ctrl,  (C and  J) IL-17Ab ICV, (D 
and  K) IL-17Ab IN, (E and L) Aβ1 – 4 2 ,  (F and  M) Aβ1 – 4 2  + IL-17Ab ICV or (G 
and  N) IL-17Ab IN-treated mice were assessed using (A and H) a Proteome Profiler 
cytokine array (in red modulated cytokines). Mean changes (± SEM) of positive spots of 
three separate experiments with n=6 mice, were expressed as INT/mm
2
 of densitometric 
values for both hippocampus (O) and prefrontal cortex (P). Comparisons were by one-way 
ANOVA with Dunnett's post hoc test; 
#P≤0.05, # # # #P≤0.0001 vs  Ctrl-treated group;  
*P≤0.05, **P≤0.01, ****P≤0.0001 indicate significance of treatment vs  Aβ1 – 4 2  peptide-
treated group.  
 
